Wednesday, November 7, 2007

The saga continues…

Saw Dr. Lisa today. Negative nodes* and clear margins, no more surgery needed—all good. Terrific news…but why aren’t we celebrating yet?
Just when I thought I would have all the information needed, I learn there is another BIG piece missing. Oh yea, my recurrence score.
Frustrated with the low accuracy of the previous (and still used) risk analysis, a more conclusive lab test has become available that uses the unique gene expression profile of a person’s tumor. This is targeted for recently diagnosed, stage I or II, node-negative, and estrogen receptor-positive patients. That rings a bell. Oncotype DX is a diagnostic test performed on the tumor tissue that quantifies the likelihood that early stage invasive breast cancer will return, or recur, and assesses the benefit from chemotherapy. This test may, or may not, be covered by insurance. Bottom line is whether my tumor expresses the genes, which will put me at risk for recurrence. High risk=chemotherapy. Low risk=radiation alone. I have chosen to proceed with this test and will wait another two weeks for the results. Since radiation follows chemo, nothing else to be done at present. Needless to say, I can relax a bit knowing the cancer is out of my body and have postponed my next haircut until I meet with a medical oncologist to discuss results. Positive affirmation: low recurrence score.

*I thought of another point regarding the lymph node evaluation. Positive lymph nodes (showing cancer cells) doesn't necessarily mean there are microscopic cancer cells elsewhere in the body. And, if the lymph nodes are negative, it doesn't mean the cancer hasn't spread elsewhere, 20-30 percent have spread even with negative nodes. Sounds like a crap shoot to me. This is why we rely on examining the characteristics of the tumor (the biomarkers), and the gene expression profile of the tumor. This is all making sense, right?

No comments: